CSIMarket
 


Eiger Biopharmaceuticals Inc   (EIGR)
Other Ticker:  
 

Cumulative Eiger Biopharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

EIGR's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

EIGR Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -36.85 % -23.44 % -34.58 % -15.86 % 20.73 %
Y / Y Current Assets Growth -61.61 % -55.31 % -34.23 % 13.71 % 43.6 %
Working Capital Ratio for Trailing Twelve Months Period 4.2 4.72 5.39 5.24 4.89
Total Ranking # 859 # 805 # 784 # 940 # 1027
Seq. Current Liabilities Growth -0.45 % -30.44 % -4.33 % -4.69 % 20.69 %
Seq. Current Assets Growth -22.5 % -27.27 % -17.55 % -17.4 % -9.77 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite year on year decrease in Eiger Biopharmaceuticals Inc 's average Current Liabilities to $16 millions, Working Capital Ratio for Trailing Twelve Months Period to 4.2 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 110 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Eiger Biopharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about EIGR
Working Capital Ratio EIGR in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 111
Sector # 569
S&P 500 # 1067


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
8.51 6.28 4.12
(Sep 30 2019)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Springworks Therapeutics Inc   11.28 
Scholar Rock Holding Corp  11.01 
Monte Rosa Therapeutics Inc   10.80 
Organovo Holdings Inc   10.75 
Invivyd Inc   10.70 
Ambrx Biopharma Inc   10.65 
Avrobio Inc   10.64 
Allogene Therapeutics inc   10.64 
Century Therapeutics inc   10.55 
Caribou Biosciences Inc   10.24 
Autolus Therapeutics Plc  10.11 
Iteos Therapeutics Inc   9.96 
Athira Pharma Inc   9.85 
Solid Biosciences Inc   9.80 
Argenx se  9.51 
Immunovant Inc   9.33 
Intensity Therapeutics Inc   9.17 
Vectivbio Holding Ag  9.14 
Allovir Inc   9.09 
Jasper Therapeutics Inc   8.99 
Inhibrx Inc   8.96 
Passage Bio inc   8.90 
Candel Therapeutics Inc   8.88 
Elevation Oncology inc   8.78 
Pluri Inc   8.72 
Humacyte Inc   8.63 
Surrozen Inc   8.57 
Ginkgo Bioworks Holdings Inc   8.38 
Biontech Se  8.26 
Tscan Therapeutics Inc   8.23 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com